AstraZeneca PLC (AZN)
Trading disclosure
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.
Learn moreKey Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
|
Mr. Pascal Claude Roland Soriot D.V.M., M.B.A.
|
CEO & Executive Director | 8.19M | -- | 1959 |
|
Dr. Aradhana Sarin M.D.
|
CFO & Executive Director | 3.63M | -- | 1974 |
|
Ms. Pam P. Cheng
|
EVP of Global opt. & IT, Chief Sust. Officer and Member of External Sust.Adv. Board | -- | -- | 1970 |
|
Mr. Joris Silon
|
Head of Investor Relations | -- | -- | -- |
|
Mr. Jeffrey Pott J.D.
|
CHRO, Chief Compliance Officer, General Counsel & Member of External Sustainability Advisory Board | -- | -- | -- |
|
Dr. Ruud Dobber Ph.D.
|
Executive Vice-President of BioPharmaceuticals Business Unit | -- | -- | -- |
|
Dr. Susan Mary Galbraith M.D., Ph.D.
|
Executive Vice President of Oncology R&D | -- | -- | 1966 |
|
Ms. Iskra Reic
|
Executive Vice President of International | -- | -- | -- |
|
Mr. David Fredrickson
|
Executive Vice-President of Oncology Haematology Business Unit | -- | -- | 1975 |
|
Ms. Ruth March FMEDSCI, O.B.E., Ph.D.
|
Senior VP of Precision Medicine - R&D Oncology | -- | -- | -- |
AstraZeneca PLC
- Sector:
- Healthcare
- Industry: Drug Manufacturers - General
- Full Time Employees:
- 96,100
Description
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Crestor, Andexxa, Onglyza, Symlin, XIGDUO XR, Atacand, Atacand HCT, Atacand Plus, Farxiga/Forxiga, Plendil, Modip, Splendil, Munobal, Flodil, Tenormin, Tenormine, Prenormine, Atenol, Zestril, Brilinta/Brilique, Komboglyze, Qtern, Wainua, Byetta, Lokelma, Seloken ZOK, Toprol-XL, Betaloc ZOK, XIGDUO, Accolate, Accoleit, Vanticon, Bricanyl Respules, Eklira Genuair/Tudorza/Bretaris, Pulmicort Turbuhaler, Symbicort Turbuhaler, Airsupra, Bricanyl Turbuhaler, Fasenra, Rhinocort, Tezspire, Bevespi Aerosphere, Daliresp/Daxas, Oxis Turbuhaler, Saphnelo, Breztri Aerosphere, Duaklir Genuair, Pulmicort Respules, and Symbicort pMDI. It also provides Beyfortus, Kavigale, Evusheld, Fluenz/FluMist, Synagis, Kanuma, Ultomiris, Koselugo, Voydeya, Soliris, Strensiq, Nexium, and other medicines. The company offers its products for ocology, cardiovascular, renal and metabolism, respiratory & immunology, vaccines and immune, and therapies for rare diseases. It serves primary and specialty care physicians through distributors and local representative offices in the United Kingdom, USA, rest of Europe, Asia, Africa, and Australasia. It has a strategic agreement with Tempus and Pathos to develop the multimodal foundation model in oncology; CSPC Pharmaceutical Group Limited to advance the discovery and development of oral candidates; Nucs AI Inc. to develop AI-driven Response Prediction for Therapeutic Radioconjugates; and Carterra, Inc. to advances lab-in-the-loop drug discovery through new scientific research collaboration. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is based in Cambridge, the United Kingdom.
Corporate Governance
Upcoming Events
October 30, 2026 at 8:00 PM UTC
AstraZeneca PLC Earnings Date
